UCB registers Phase 2 SCALA trial of galvokimig in COPD with chronic bronchitis
UCB Biopharma is recruiting for a new Phase 2 study testing galvokimig against placebo in moderate-to-severe COPD patients with chronic bronchitis.
UCB Biopharma's week centered on a single new trial registration for its investigational biologic galvokimig.
- Galvokimig (UCB9741), a biologic, is being tested in a Phase 2 trial called "SCALA" in patients with moderate-to-severe Chronic Obstructive Pulmonary Disease With Chronic Bronchitis (SCALA)1. The study aims to compare the efficacy of galvokimig versus placebo in the time to the first acute exacerbation of chronic obstructive pulmonary disease (AECOPD)1 in this patient population. The trial is listed as recruiting, with an estimated enrollment of 402 participants (estimated)1 and a primary completion date of 2029-06-29 (estimated)1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.